The FDA has approved a supplemental Biologics License Application for Fluzone High-Dose Quadrivalent (Influenza Vaccine), from Sanofi, for use in...
The FDA has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (vaccine), from Sanofi, to include efficacy data...
Sanofi Pasteur, the vaccines division of Sanofi announced that The New England Journal of Medicine published positive results from a...
The FDA has approved the 0.5mL dose of its influenza vaccine, Fluzone Quadrivalent, from Sanofi Pasteur, for treating children falling...
Sanofi Pasteur, has announced that the FDA has approved the supplemental biologics license application (sBLA) for licensure of its four-strain...
Novavax, Inc., announced publication of complete results from a pivotal Phase III clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M adjuvant, in The Lancet Infectious Diseases (Lancet ID).
Adial Pharmaceuticals, Inc., announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD 04 (low-dose ondansetron), the Company’s lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD)
Merck Inc. known as MSD outside of the United States and Canada, announced that Health Canada has approved a new indication for Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]).
Objective: To evaluate the efficacy of IFX 7.5 to 10 mg/kg, with a maintenance frequency every 4 weeks.